Compare Eaton Corporation plc (ETN) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eaton Corporation plc vs Viatris Inc — how do they compare? Eaton Corporation plc trades at $396.01 (market cap $160.31B), while Viatris Inc trades at $17.29 (market cap $19.44B). The key difference: Eaton Corporation plc is far larger — about 8.2× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.88%). Which is the better fit depends on your goals.
| ETN | VTRS | |
|---|---|---|
Market Cap | $160.31B | $19.44B |
Sector | Technology | Health |
52-Week High | $435.78 | $17.39 |
52-Week Low | $315.82 | $8.74 |
Enterprise Value | $181.40B | $31.65B |
Dividend Yield | 1.07% | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eaton Corporation (ETN) trades at $404.20, down 2.72% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.81 exceeding expectations. Analyst consensus is overwhelmingly positive with 25 buy ratings and a $449.50 price target. Recent news highlights growth in AI data center power infrastructure and a new sustainability report showing 40% emissions reduction.
ETN's outlook remains favorable due to robust demand in data center and aerospace markets, though elevated valuation multiples (P/E 40.4) pose a risk if growth moderates. The stock offers upside to consensus targets but faces execution risks from large 2026 investing outflows. Dividend payments provide income support with the next $1.10 distribution scheduled for May 29, 2026.
Viatris (VTRS) trades at $16.31, down 0.49% on the day, with technical indicators showing a bullish moving average trend despite recent price weakness. The company has beaten earnings expectations for three consecutive quarters, though it reported a significant net loss of -$3.51B in 2025. Analyst consensus leans toward 'Hold' with a $20 price target, representing 22.6% upside potential. Recent positive developments include FDA acceptance of its fast-acting meloxicam NDA and promising Phase 3 results for VR-205 in Japan.
The outlook presents a value recovery opportunity with reasonable valuation metrics (P/S: 1.34, P/B: 1.33) and improving cash flow trends, but significant risks remain including persistent negative profitability margins, high debt levels, and intense generic drug competition. The stock's direction will depend on successful pipeline execution and debt reduction progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
